NYSEArca - Delayed Quote USD

First Trust Dow Jones Internet Index Fund (FDN)

197.57 -0.63 (-0.32%)
At close: April 24 at 4:00 PM EDT
193.88 -3.69 (-1.87%)
After hours: April 24 at 7:59 PM EDT
Loading Chart for FDN
DELL
  • Previous Close 198.20
  • Open 199.22
  • Bid --
  • Ask --
  • Day's Range 196.18 - 199.94
  • 52 Week Range 137.63 - 208.31
  • Volume 250,299
  • Avg. Volume 408,953
  • Net Assets 6.42B
  • NAV 198.32
  • PE Ratio (TTM) 37.06
  • Yield 0.00%
  • YTD Daily Total Return 6.24%
  • Beta (5Y Monthly) 1.25
  • Expense Ratio (net) 0.52%

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the securities that comprise the index. The index is designed to measure the performance of the largest and most actively traded securities issued by U.S. companies in the Internet industry. The index is a composite of its two sub-indices, the Dow Jones Internet Commerce Index and the Dow Jones Internet Services Index. It is non-diversified.

First Trust Advisors L.P.

Fund Family

Technology

Fund Category

6.42B

Net Assets

2006-06-19

Inception Date

Performance Overview: FDN

Trailing returns as of 4/23/2024. Category is Technology.

YTD Return

FDN
6.24%
Category
8.66%
 

1-Year Return

FDN
38.63%
Category
31.83%
 

3-Year Return

FDN
4.91%
Category
3.17%
 

People Also Watch

Holdings: FDN

Top 10 Holdings (53.25% of Total Assets)

SymbolCompany% Assets
AMZN
Amazon.com, Inc. 10.08%
META
Meta Platforms, Inc. 8.02%
GOOGL
Alphabet Inc. 5.75%
CRM
Salesforce, Inc. 5.28%
NFLX
Netflix, Inc. 5.10%
GOOG
Alphabet Inc. 4.86%
CSCO
Cisco Systems, Inc. 4.54%
PYPL
PayPal Holdings, Inc. 3.35%
ANET
Arista Networks, Inc. 3.16%
ABNB
Airbnb, Inc. 3.12%

Sector Weightings

SectorFDN
Technology   42.01%
Healthcare   2.95%
Real Estate   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Recent News: FDN

Research Reports: FDN

  • Analyst Report: Biogen Inc.

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

    Rating
    Price Target
     
  • FTNT: What does Argus have to say about FTNT?

    FORTINET INC has an Investment Rating of BUY; a target price of $71.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • FTNT: Raising target price to $72.00

    FORTINET INC has an Investment Rating of HOLD; a target price of $72.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
     
  • FTNT: What does Argus have to say about FTNT?

    FORTINET INC has an Investment Rating of HOLD; a target price of $71.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.

    Rating
    Price Target
     

Related Tickers